2024-10-27 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of products and services, including pharmaceuticals, medical devices, diagnostics, and nutritionals.

**1. Performance Comparison:**

* **Cumulative Return:** ABT has a cumulative return of 108.65%, while the S&P 500 (VOO) has a cumulative return of 135.48%. This puts ABT **26.83%** behind VOO in terms of cumulative return. 
* **Relative Strength:** ABT's relative strength is currently at the **15.19th percentile** based on historical data. This means that its current performance is better than approximately 15% of its historical performance against the S&P 500.

**2. Recent Price Movement:**

* **Last-market:** 114.24
* **5-Day Moving Average:** 117.21
* **20-Day Moving Average:** 115.46
* **60-Day Moving Average:** 113.67

**3. Technical Indicators:**

* **RSI:** 63.5 - This indicates that the stock is currently in the **overbought territory**, suggesting potential for a short-term pullback.
* **PPO:** 0.01 - This indicates a **weak bullish signal**. 
* **Delta_Previous_Relative_Divergence:** 3.96 (+) - This suggests **short-term upward momentum**.
* **Expected Return:** 0.0% - This indicates that over a long-term horizon (2 years or more), ABT is expected to have a **similar return** to the S&P 500.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

Abbott's recent earnings have been **generally consistent** with the past year, showing a slight decline in the most recent quarter. The company is expected to **continue its stable growth trajectory** in the coming quarters, driven by its diversified product portfolio and strong global presence.

**5. News & Recent Issues:**

* **Recent Earnings News:** Abbott Laboratories reported its Q2 2024 earnings on July 31st, 2024. The company exceeded analyst expectations on both earnings and revenue, with EPS coming in at $0.74 compared to an expected $0.71. Revenue reached $10.38 billion, beating expectations of $10.18 billion. (Source: Shacknews, other financial news sources)
* **Recent Market Outlook:**  The company has a **strong market position**, with a wide range of products and services catering to various segments of the healthcare industry.  Analysts have highlighted the company's **stable earnings growth, consistent dividend payouts, and strong cash flow generation**. (Source: FINBOLD, other financial news sources)
* **Analyst Opinions & Performance Highlights:**  Analysts are generally bullish on ABT's future prospects.  They expect the company to benefit from the growing demand for healthcare products and services globally. (Source: FINBOLD, other financial news sources)

**6. Overall Analysis:**

Abbott Laboratories appears to be a **solid and consistent performer**, with a solid track record of earnings growth and a strong market position. However, the stock is currently trading in the overbought territory, suggesting potential for a short-term pullback.  Despite its recent underperformance compared to the S&P 500, analysts expect ABT to continue its stable growth trajectory, making it a suitable option for long-term investors looking for a relatively stable and predictable investment. 

**7. Recommendations:**

* **Long-term investors:** ABT is a suitable option for investors looking for a long-term investment in the healthcare sector.
* **Short-term investors:** The current overbought conditions suggest a potential short-term pullback, so investors may want to wait for a better entry point.
* **Active Traders:**  The recent price movement and technical indicators suggest potential short-term trading opportunities.

**Disclaimer:** This report is for informational purposes only and should not be considered financial advice. 
